Monika Vainorius

1.1k total citations
23 papers, 731 citations indexed

About

Monika Vainorius is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Monika Vainorius has authored 23 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 14 papers in Epidemiology and 7 papers in Infectious Diseases. Recurrent topics in Monika Vainorius's work include Hepatitis C virus research (20 papers), Liver Disease Diagnosis and Treatment (14 papers) and HIV/AIDS drug development and treatment (7 papers). Monika Vainorius is often cited by papers focused on Hepatitis C virus research (20 papers), Liver Disease Diagnosis and Treatment (14 papers) and HIV/AIDS drug development and treatment (7 papers). Monika Vainorius collaborates with scholars based in United States, Germany and Israel. Monika Vainorius's co-authors include Michael Fried, David R. Nelson, Lucy Akushevich, Joseph K. Lim, Alexander Kuo, Mark Sulkowski, Adrian M. Di Bisceglie, Norah A. Terrault, K. Rajender Reddy and Anna S. Lok and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Monika Vainorius

23 papers receiving 719 citations

Peers

Countries citing papers authored by Monika Vainorius

Since Specialization

Citations

This map shows the geographic impact of Monika Vainorius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monika Vainorius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monika Vainorius more than expected).

Fields of papers citing papers by Monika Vainorius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monika Vainorius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monika Vainorius. The network helps show where Monika Vainorius may publish in the future.

Co-authorship network of co-authors of Monika Vainorius

This figure shows the co-authorship network connecting the top 25 collaborators of Monika Vainorius. A scholar is included among the top collaborators of Monika Vainorius based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monika Vainorius. Monika Vainorius is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL 2021 ·Blood ·Nitin Jain, Hagop M. Kantarjian, Scott R. Solomon, Fiona He, Craig S. Sauter, Christopher R. Heery, Alan F. List, Mark Johnson, Yu Lou, Monika Vainorius, Koen van Besien, Adam J. Olszewski, Anthony S. Stein, Bijal Shah	14
2	Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies 2021 ·Blood ·Bijal Shah, Caron A. Jacobson, Scott R. Solomon, Nitin Jain, Mark Johnson, Monika Vainorius, (unknown), Christopher R. Heery, Alan F. List, Fiona He, Ran Reshef, Luke P. Akard, Craig S. Sauter, Adam J. Olszewski, Abhinav Deol, Koen van Besien	24
3	Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL. 2021 ·Journal of Clinical Oncology ·Bijal Shah, Caron A. Jacobson, Scott R. Solomon, Nitin Jain, Monika Vainorius, Christopher R. Heery, Fiona He, Ran Reshef, Alex F. Herrera, Luke P. Akard, Craig S. Sauter	19
4	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort 2020 ·Journal of Hepatology ·Elizabeth C. Verna, Giuseppe Morelli, Norah A. Terrault, Anna S. Lok, Joseph K. Lim, Adrian M. Di Bisceglie, Stefan Zeuzem, Charles Landis, Paul Y. Kwo, Mohamed A. Hassan, Michael P. Manns, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael Fried, K. Rajender Reddy	81
5	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy 2019 ·Gastroenterology ·Anna S. Lok, Mark Sulkowski, Jens Kort, Ira Willner, K. Rajender Reddy, Mitchell L. Shiffman, Mohamed A. Hassan, Brian L. Pearlman, Federico Hinestrosa, Ira M. Jacobson, Giuseppe Morelli, Joy Peter, Monika Vainorius, (unknown), Michael Fried, Gary P. Wang, Wenjing Lü, Lois Larsen, David R. Nelson	34
6	THU-181-Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study 2019 ·Journal of Hepatology ·Richard K. Sterling, Stefan Zeuzem, Tania M. Welzel, Michael P. Manns, K. Rajender Reddy, Norah A. Terrault, Ziv Ben Ari, Irine Vodkin, Arifa Toor, Monika Vainorius, Lucy Akushevich, Michael Fried, David R. Nelson, (unknown)	1
7	956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study 2019 ·Gastroenterology ·Richard K. Sterling, Stefan Zeuzem, Tania M. Welzel, Michael P. Manns, K. Rajender Reddy, Norah A. Terrault, Ziv Ben‐Ari, Irine Vodkin, Arifa Toor, Monika Vainorius, Lucy Akushevich, Michael Fried, David R. Nelson, Mark Sulkowski	2
8	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis 2019 ·Hepatology Communications ·Kavita Radhakrishnan, Adrian M. Di Bisceglie, K. Rajender Reddy, Joseph K. Lim, Josh Levitsky, Mohamed A. Hassan, Jama M. Darling, Jordan J. Feld, Lucy Akushevich, Monika Vainorius, David R. Nelson, Michael Fried, Robert S. Brown, Norah A. Terrault	8
9	Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis 2018 ·Clinical Gastroenterology and Hepatology ·Joseph K. Lim, (unknown), Mitchell L. Shiffman, Anna S. Lok, Stefan Zeuzem, Norah A. Terrault, James Park, Charles Landis, Mohamed A. Hassan, Joel E. Gallant, Alexander Kuo, Paul J. Pockros, Monika Vainorius, Lucy Akushevich, (unknown), Michael Fried, David R. Nelson, Ziv Ben‐Ari	13
10	Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study 2017 ·Journal of Hepatology ·Mandana Khalili, Tania M. Welzel, (unknown), Glen Lutchman, David R. Nelson, Brian B. Borg, A.S. Lok, A Ramani, Nancy Reau, Monika Vainorius, Michael Fried, Charles Landis	3
11	Incidence of and predictors for direct acting antiviral treatment failure among 3909 hepatitis C genotype 1 infected adults: real world outcomes from HCV TARGET 2017 ·Journal of Hepatology ·Mark Sulkowski, K. Rama Reddy, David R. Nelson, Joseph K. Lim, Joseph Galati, Alexander Kuo, Norah A. Terrault, A.S. Lok, Brian L. Pearlman, Monika Vainorius, Lucy Akushevich, Michael Fried, Adrian M. Di Bisceglie	1
12	Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study 2017 ·Hepatology ·Varun Saxena, Vandana Khungar, Elizabeth C. Verna, Josh Levitsky, Robert S. Brown, Mohamed A. Hassan, Mark Sulkowski, Jacqueline G. O’Leary, Farrukh M. Koraishy, Joseph Galati, Alexander Kuo, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael Fried, Norah A. Terrault, K. Rajender Reddy	116
13	Safety and efficacy of elbasvir and grazoprevir with or without ribavirin for the treatment of hepatitis C virus genotype 1: results of the hepatitis C virus-TARGET study 2017 ·Journal of Hepatology ·Brian L. Pearlman, Glen Lutchman, Mitchell L. Shiffman, Jaina Patel, Lynn M. Frazier, Joseph Galati, (unknown), A Ramani, Monika Vainorius, David R. Nelson, (unknown), Mandana Khalili, Ziv Ben‐Ari	1
14	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study 2016 ·Gut ·Tania M. Welzel, David R. Nelson, Giuseppe Morelli, Adrian M. Di Bisceglie, K. Rajender Reddy, Alexander Kuo, Joseph K. Lim, Jama M. Darling, Paul J. Pockros, Joseph Galati, Lynn M. Frazier, Saleh A. Alqahtani, Mark Sulkowski, Monika Vainorius, Lucy Akushevich, Michael Fried, Stefan Zeuzem	61
15	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response 2016 ·Gastroenterology ·Norah A. Terrault, Stefan Zeuzem, Adrian M. Di Bisceglie, Joseph K. Lim, Paul J. Pockros, Lynn M. Frazier, Alexander Kuo, Anna S. Lok, Mitchell L. Shiffman, Ziv Ben Ari, Lucy Akushevich, Monika Vainorius, Mark Sulkowski, Michael Fried, David R. Nelson	158
16	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study 2016 ·Clinical Infectious Diseases ·Jordan J. Feld, Raoel Maan, Stefan Zeuzem, Alexander Kuo, David R. Nelson, Adrian M. Di Bisceglie, Michael P. Manns, (unknown), Lynn M. Frazier, Richard K. Sterling, Mark E. Mailliard, Monica Schmidt, Lucy Akushevich, Monika Vainorius, Michael Fried	36
17	Safety and Efficacy of New Daa Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Interval Results from the HCV-Target Study 2016 ·Journal of Hepatology ·K. Rajender Reddy, Mark Sulkowski, Md. Imtaiyaz Hassan, Josh Levitsky, Jacqueline G. O’Leary, Robert S. Brown, Elizabeth C. Verna, Alexander Kuo, R. Todd Stravitz, Joseph K. Lim, Vijay Saxena, David R. Nelson, Paul H. Hayashi, Monika Vainorius, (unknown), Norah A. Terrault	3
18	Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1 2015 ·Journal of Gastroenterology and Hepatology Research ·Giuseppe Morelli, Roberto J. Firpi, (unknown), Joy Peter, (unknown), Monika Vainorius, Shelley George, Abel De La Rosa, (unknown), (unknown), Richard F. Arrendale, Tara L. Kieffer, Varun Garg, Michael Fried, David R. Nelson	2
19	O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience 2015 ·Journal of Hepatology ·K. Rajender Reddy, Joseph K. Lim, Alexander Kuo, Adrian M. Di Bisceglie, Hugo E. Vargas, Joseph Galati, G. Morelli, Gregory T. Everson, Paul Y. Kwo, Robert S. Brown, Mark Sulkowski, Thomas G. Stewart, (unknown), Monika Vainorius, Joy Peter, David R. Nelson, Michael Fried, Michael P. Manns	27
20	Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET 2014 ·Journal of Hepatology ·Stuart C. Gordon, Andrew J. Muir, Joseph K. Lim, Brian L. Pearlman, Curtis K. Argo, Ananthakrishnan Ramani, Benedict Maliakkal, Imtiaz Alam, Thomas G. Stewart, Monika Vainorius, Joy Peter, David R. Nelson, Michael Fried, K. Rajender Reddy	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact